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Physicians use the Common Terminology Criteria for Adverse 
Events (CTCAE), as defined by the US National Cancer Institute 
(NCI), as a standard classification system for reporting adverse 
events in cancer clinical trials (1). An adverse event is defined as an 
unfavorable and unintended sign, symptom, or disease temporarily 
associated with the use of a medical treatment or procedure; 
adverse events can include abnormal laboratory findings. 
Developed initially in 1982 by the NCI’s Cancer Therapy 
Evaluation Program, this rating system is currently in its fourth 
version. The rapid pace of revisions reflects the changing needs of 
investigators for usable adverse events criteria and the increasing 
complexity of cancer clinical trials. In version 4 of the NCI-
CTCAE, there are 790 specific items, with approximately 10% of 
the adverse events representing symptoms such as fatigue, pain, 
and nausea.
Recently, it has become common practice in major American 
and European adult cancer clinical trial cooperative group studies 
to use patient-reported assessments of adverse events alongside 
clinician-reported assessments (2–4). This trend reflects the 
increasing importance of the patient’s voice in cancer treatment, 
especially because studies (5–7) have shown that patient-reported 
outcomes can improve the accuracy and efficiency of symptomatic 
adverse event data collection.
Several articles (8–10) have reported that clinician-reported 
assessments of symptoms tend to underestimate, or in some cases 
overestimate, the symptom burden compared with patient ratings 
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C-index = .63 with clinician data only; P <.001), vomiting (C-index = .64 vs .62; P = .01), nausea (C-index = .65 vs 
.62; P < .001), and constipation (C-index = .62 vs .61; P = .01).
 Conclusion Patients provide a subjective measure of symptom severity that complements clinician scoring in predicting 
overall survival.
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and that substantial variability might exist between physician and 
patient ratings, particularly for more subjective symptoms such as 
fatigue (11,12). Therefore, Varricchio and Sloan (13) have advo-
cated the use of self-reported measures for many symptoms 
because of their subjective nature.
Bruner (14) reported several flaws with regard to clinician-
reports on the CTCAE, such as high variability in scoring among 
clinicians and institutions and a lack of standardization in the 
implementation and recording of the tool. Moreover, these 
authors pointed out that there is no psychometric testing on the 
NCI-CTCAE and for most adverse events, no formal evidence 
exists as to what separates grade 1 toxicity from grade 2 and 3 and 
whether this separation represents clinical significance for the 
patient. The collection of patient-reported outcomes using vali-
dated psychometric questionnaires on a patient’s first visit might 
augment these data to provide a better assessment tool for health-
care professionals who must choose the right treatments for their 
patients and must assess whether they are eligible to enter clinical 
trials in which toxic effects might become a too-high burden for 
some individuals.
In addition to more accurate assessments of symptoms, patient-
reported outcomes might also provide some valuable information 
with regard to overall survival. A large prospective study by 
Christakes and Lamont (15) demonstrated that clinicians are often 
inaccurate in their prognosis for terminally ill patients; in that 
study, they overestimated survival by a factor of 5.3. In an extensive 
review of more than 39 selected trials, Gotay et al. (16) reported 
that patient-reported outcomes have prognostic value of overall 
survival in 36 of the 39 studies; however, the trials that they 
analyzed often used a wide variety of different patient-reported 
outcome measurements. Several large pooled studies (17,18) mod-
eled the prognostic value of patient-reported outcomes using a 
single standard of measure and showed that incorporating patient-
reported outcomes alongside clinician data improved the accuracy 
of predicting overall survival.
The aim of this study was to assess the level of agreement 
between clinician and patient reports of symptoms collected at 
baseline and to examine the value of each data source, alone and in 
combination, for predicting overall survival. The added value of 
patient-reported outcomes data was quantified by the degree of 
accuracy conferred by using both ratings to contribute to the pre-
diction of overall survival in cancer patients. The analysis assessed 
the extent to which patient perspectives, clinician ratings, and 
the extent of agreement between these ratings contributes to esti-
mating cancer survival.
Methods
Patients and Data
This study was conducted using a secondary dataset collected from 
14 closed phase III European Organization for Research and 
Treatment of Cancer (EORTC) randomized controlled trials ini-
tiated at the EORTC between 1990 and 2002. The 14 EORTC 
randomized controlled trials, including a total of 3719 patients, 
were individually selected based on the availability of both clinician- 
and patient-reported symptom scoring at baseline and the use of 
overall survival as the primary outcome. Patients for whom a 
patient or clinician score was missing for a given symptom were 
excluded from further analysis, leaving a total of 2279 patients for 
whom data were collected for one or more symptoms. Nine of the 
14 trials provided both patient and clinician scores for pain; five 
trials provided both patient and clinician scores for vomiting; six 
trials provided both patient and clinician scores for nausea; six 
trials provided both patient and clinician scores for diarrhea; five 
trials provided both patient and clinician scores for fatigue; four 
trials provided both patient and clinician scores for constipation.
All of the 14 selected trials measured symptom burden using 
the EORTC Quality of Life Core questionnaire (QLQ-C30) that 
was developed to assess the health-related quality of life of cancer 
patients [(19); see Supplementary Materials, available online]. It 
surveys 15 health-related quality of life parameters; in addition to 
assessing the symptoms pain, fatigue, appetite loss, nausea and/or 
vomiting, diarrhea, constipation, sleep disturbance, and financial 
impact, it was also designed to measure the physical, psychological, 
and social functioning of cancer patients. The measures of func-
tioning will not be discussed in this article because of the absence 
of comparable ratings by clinicians. In the EORTC QLQ-C30 
CONTEXT AND CAVEATS
Prior knowledge
Clinicians regularly use the National Cancer Institute’s Common 
Terminology Criteria for Adverse Events (NCI-CTCAE) system to 
report cancer patients’ symptoms in clinical trials. It was suggested 
that the inclusion of patients’ self-assessments of their symptoms 
might improve models to predict their overall survival.
Study design
Clinician-reported data regarding six common patient symptoms 
(NCI-CTCAE) and similar patient-reported data from a European 
Organization for Research and Treatment of Cancer Quality of Life 
questionnaire (EORTC QLQ-C30) were collected at baseline from 14 
EORTC randomized controlled trials involving 2279 cancer patients. 
The authors examined the extent to which responses from clini-
cians and patients were correlated and concordant. They also 
assessed whether the inclusion of patients’ responses improved 
Cox models to predict overall survival.
Contribution
For each of the six symptoms studied (pain, fatigue, vomiting, 
nausea, diarrhea, and constipation), patient-reported scores did 
differ somewhat from clinician-reported scores. Both scores made 
a positive and additive contribution to the predictive accuracy of 
survival models.
Implication
Patient-reported data can complement clinician-reported data to 
achieve more reliable measurements of clinical outcomes.
Limitations
Relative to other factors, both patient and clinician scores of symp-
toms make a small contribution to the Cox models. Furthermore, 
the NCI-CTCAE and EORTC QLQ-30 were intended for different 
purposes and so it is difficult to exactly compare them. Last, 
patients with severe symptom burdens would be unlikely to be 
among this study population, which consisted of new enrollees in 
randomized trials.
From the Editors
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questionnaire, the patient rated his or her symptoms on a 4-point 
ordinal scale in which a score of 1 meant “not at all,” a score of 2 
meant “a little,” a score of 3 meant “quite a bit,” and a score of 4 
meant “very much” (20). Standard EORTC QLQ-C30 scoring of 
three symptoms uses multi-item subscales: for fatigue, there were 
three items scored; for nausea and vomiting, two items scored; and 
for pain, two items scored. In this study, nausea and/or vomiting 
was scored as two separate items to correspond with the NCI-
CTCAE criteria, vomiting and nausea.
Baseline clinician assessments were performed in these 14 
EORTC trials using version 2 of the NCI-CTCAE questionnaire 
(21), the accepted version at the time the 14 trials started (1990–
2002). In this assessment instrument, clinicians were asked to 
assess the patient in terms of a predefined set of symptoms, as 
specified in the protocol, and to report their score on a case report 
form. For each symptom, a description was provided to facilitate 
physician ratings, which in this case were on a 5-point scale. In 
version 2.0, “grades” 0 through 4 were associated with unique 
clinical descriptions of the severity of adverse events based on 
the following general criteria: a score of 0 meant “none or 
normal.” a score of 1 meant “mild,” a score of 2 meant “moderate,” 
a score 3 meant “severe,” and a score of 4 meant “life threatening 
or disabling” (see questionnaire in Supplementary Materials, 
available online).
Statistical Methods
The mean scores and variability of the selected baseline symptoms 
were calculated for both the EORTC QLQ-C30 and NCI-
CTCAE measures. Spearman correlation coefficients (r) were 
calculated as a simple exploratory statistic to study the magnitude 
of agreement between patient and clinician scoring; r ranged from 
21 to 1, whereby a higher absolute value indicated a stronger 
correlation. Cohen (22) suggested that a correlation coefficient 
that is less than .30 indicates a weak relationship, a value between 
.30 and .50 indicates a moderate relationship, and a value greater 
than .50 indicates a strong relationship.
“Exact agreement” was defined as the proportion of identical 
paired responses between the EORTC QLQ-C30 and NCI-
CTCAE assessment instruments. We considered each of the fol-
lowing pairs to be identical responses: EORTC QLQ-C30 score 1 
vs NCI-CTCAE score 0; EORTC QLQ-C30 score 2 vs NCI-
CTCAE score 1; EORTC QLQ-C30 score 3 vs NCI-CTCAE 
score 2; EORTC QLQ-C30 score 4 vs NCI-CTCAE score 3 and 
4 combined. The level of exact agreement between patient vs 
clinician symptom rating was assessed using the Cohen kappa 
coefficient (k) (23). This measure is used to assess the degree to 
which two or more raters, examining the same data, agree when it 
comes to assigning the data to categories. Landis and Koch (24) 
proposed categories for judging kappa values: a k value less than 
0.00 means poor agreement; k between .00 and .20, slight 
agreement; k between .21 and .40, fair agreement; k between .41 
and .60, moderate agreement; k between .61 and .80, substantial 
agreement; and k between .81 and 1.00, almost perfect agreement.
We evaluated the accuracy of clinician and patient scoring to 
predict overall survival, alone and in combination, after adjusting 
for age (≤60 vs >60 years) and sex (male vs female) (both prognostic 
sociodemographic variables) and metastasis (yes vs no), World 
Health Organization (WHO) performance status (WHO 0–1 vs 
WHO 2–3), and cancer site (all clinical variables). We calculated 
the ability of four Cox proportional hazards models to predict 
overall survival. The assumption of proportionality in the four 
models was assessed by investigating the weighted Shoenfeld resid-
uals for each predictor. Model 1 included the sociodemographic 
and clinical variables alone; model 2 included the sociodemo-
graphic and clinical variables and the patient symptom ratings; 
model 3 included the sociodemographic and clinical variables and 
the clinician symptom ratings; and model 4 included the sociode-
mographic and clinical variables and both the patient and the 
clinician symptom ratings.
The predictive accuracy of four Cox models was investigated 
using Harrell concordance index (C-index; C), which is the area 
under the receiver-operator curve (ROC curve) adapted for sur-
vival data. The C-index estimates the percentage of correct predic-
tions: that is, the percentage of patient pairs in which the predicted 
(according to the model) and observed (according to the data) 
survival order are in agreement (concordance), with C = .5 for a 
random model with no variables and C = 1 for a perfect order 
concordance (25). Differences between the C-indices were assessed 
using the jackknife method (26). All P values less than .05 were 
considered statistically significant, and all P values were from 
two-sided tests. In addition to the C-index, we also performed the 
Concordance Probability Estimate (CPE) measure of discrimination. 
This measure is based on the method of Gönen and Heller (27) 
and measures discriminative accuracy in the presence of censoring. 
SAS (SAS Institute Inc, Cary, NC) software was used for statistical 
analysis.
Results
Both clinician and patient assessments at baseline could be 
retrieved for the following six symptoms: pain, fatigue, vomiting, 
nausea, diarrhea, and constipation. In all of the 14 selected ran-
domized controlled trials, NCI-CTCAE version 2.0 was used for 
clinician assessments and either EORTC QLQ-C30 version 1, 2, 
or 3 was used for patient assessments. The three versions of 
EORTC QLQ-C30 differed with regard to scoring of three 
parameters that were not our focus (the role functioning scale, the 
physical functioning scale, and the overall health status scale) and 
therefore, the version used did not influence the analysis of 
the symptoms that we studied (28,29). Among the 14 available 
randomized controlled trials, nine trials, including a total of 1467 
patients, reported both clinician and patient assessments of pain. 
Five of the 14 available randomized controlled trials, involving 
1237 patients, reported clinician and patient assessments of 
fatigue; five trials including 824 patients provided the necessary 
information on vomiting; six trials including 813 patients had 
information on nausea; six trials including 815 patients had infor-
mation on diarrhea; and four trials including 751 patients had in-
formation on constipation. The distribution of age, sex, WHO 
performance status, and distant metastasis status among the partic-
ipants in the trials evaluated for each symptom were comparable. 
For each of the symptoms, the percentage of patients who had 
WHO 0–1 performance status was much higher than the per-
centage of patients who had a low WHO 2–3 performance status. 
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This might be explained by the inclusion criteria of the selected 
trials; in general, patients with low performance status were 
excluded from participation in EORTC randomized controlled 
trials; however, the cancer sites varied among the trials that could 
be used to evaluate each symptom (Table 1).
First, we examined the mean scores and 95% confidence inter-
vals (CIs) from the patient assessments (EORTC QLQ-C30) vs 
clinician assessments (NCI-CTCAE) for each of the selected 
symptoms (Table 2). We noticed that reporting of fatigue was 
highly variable between patient and clinician assessments (patient 
score = 2.10 vs clinician score = 1.36). However, there was low 
variability in the reporting of vomiting (patient score = 1.11 vs 
clinician score = 1.18) and constipation (patient score = 1.50 vs 
clinician score = 1.11).
For exploratory purposes, we calculated the Spearman correla-
tion coefficient (r) and the kappa coefficient (k) to quantify the 
level of agreement between the patient- and clinician-reported 
assessments of adverse event symptoms (Table 3). The Spearman 
correlation between the clinician and patient scorings was low for 
diarrhea (r = .20) and pain (r = .58), indicating weak to moderate 
relationships between the two scorings. Low kappa coefficients 
were also reported for some symptoms, for example, fatigue 
(k = .07) and pain (k = .29). According to Landis and Koch (24), 
these k values approximate low to fair agreement between the two 
assessors.
Next, we investigated whether patient and clinician ratings, 
either alone or together, might predict survival after adjustment 
for the prognostic sociodemographic variables, age and sex, and 
the clinical variables, metastasis, performance status, and cancer 
site. The C-index, which calculates the accuracy of the four Cox 
models to predict overall survival (Table 4), shows that for all six 
symptoms, the relative gain in predictive accuracy of survival esti-
mation compared with a random model with no variables (C = 0.5) 
is the highest when taking into consideration the prognostic 
sociodemographic and clinical variables (model 1), indicating their 
strong predictive value. Models to which patient and clinician 
symptom ratings were added, either alone or together, had 
improved predictive accuracy compared with a similar model that 
used only sociodemographic and clinical variables. When com-
paring how adding patient-reported scoring (model 2) vs clinician-
reported scoring (model 3) next to clinical and sociodemographic 
variables affected the predictive accuracy of the model, we found 
statistically significant differences for four of the six symptoms. 
Patient-reported outcomes were more predictive than clinician-
reported outcomes for fatigue (C-index for model 2 vs model 3 = .66 
vs .63; P <.001), vomiting (C-index = .64 vs .62; P = .01), nausea 
(C-index = .65 vs .62; P <.001), and constipation (C-index = .62 vs .61; 
P = .03). When comparing the effect of fortifying the model with 
patient plus clinician scoring (model 4) vs the clinician scoring 
alone (model 3), we found statistically significant differences for 
the inclusion of the same four symptoms: fatigue (C-index for 
model 4 vs model 3 = .67 vs .63; P < .001), vomiting (C-index = .64 
vs .62; P = .01), nausea (C-index = .65 vs .62; P <.001), and consti-
pation (C-index = .62 vs .61; P = .01). In data not shown, similar 
results were noticed between the two methods for the CPE 
measure (27).
Table 1. The clinical and sociodemographic variables for the included patients and trials for the symptoms pain, fatigue, vomiting, 
nausea, diarrhea, and constipation*
Clinical and  
sociodemographic  
variables
Pain, No. (%)  
(nine RCTs;  
n = 1467)
Fatigue,  
No. (%)  
(five RCTs;  
n = 1237)
Vomiting,  
No. (%)  
(five RCTs;  
n = 824)
Nausea,  
No. (%)  
(six RCTs;  
n = 813)
Diarrhea,  
No. (%)  
(six RCTs;  
n = 815)
Constipation, 
No. (%)  
(four RCTs;  
n = 751)
Age, y      
 ≤60 585 (39.9) 827 (66.9) 491 (59.6) 481 (59.2) 487 (59.8) 476 (63.4)
 >60 882 (60.1) 410 (33.1) 333 (40.4) 332 (40.8) 328 (40.2) 275 (36.6)
Performance status      
 WHO 0-1 1,213 (82.7) 1,118 (90.4) 753 (91.4) 742 (91.3) 745 (91.4) 696 (92.7)
 WHO 2-3 254 (17.3) 118 (9.5) 71 (8.6) 71 (8.7) 70 (8.6) 55 (7.3)
Sex      
 Male 1,018 (69.4) 731 (59.1) 501 (60.8) 501 (61.6) 497 (61) 430 (57.3)
 Female 449 (30.6) 506 (40.9) 323 (39.2) 312 (38.4) 318 (39) 321 (42.7)
Metastasis      
 No 183 (12.5) 107 (8.6) 108 (13.1) 107 (13.2) 108 (13.3) 108 (14.4)
 Yes 1,214 (82.8) 633 (51.2%) 715 (86.8%) 705 (86.7%) 706 (86.6%) 642 (85.5%)
Cancer site      
 Brain 0 496 (40) 0 0 0 0
 Colon or rectum 371 (25.3) 370 (29.9) 378 (45.9) 377 (46.4) 375 (46) 376 (50)
 Lung 343 (23.4) 0 0 0 0 0
 Ovary 69 (4.7) 0 0 0 0 0
 Prostate 542 (36.9) 0 69 (8.4) 69 (8.5) 68 (8.3) 0
 Breast 82 (5.6) 8 (0.7) 8 (0.9) 0 8 (1) 8 (1.1)
 Melanoma 60 (4.1) 304 (24.6) 308 (37.4) 306 (37.6) 303 (37.2) 306 (40.8)
 Pancreas 0 59 (4.8) 61 (7.4) 61 (7.5) 61 (7.5) 61 (8.1)
* Individual patient data for the variable “performance status” were unavailable for the symptom fatigue (n = 1), and data for the variable “metastasis” were 
unavailable for the symptoms pain (n = 70), fatigue (n = 497), vomiting (n = 1), nausea (n = 1), diarrhea (n = 1), and constipation (n = 1). For this reason,  
percentages do not always add up to 100%. RCT = randomized controlled trial; WHO = World Health Organization.
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Discussion
The goal of this study was to determine whether estimation of 
overall survival could be improved by including both baseline 
patient- and/or clinician-reported scores of clinical symptoms in a 
large heterogeneous dataset of cancer patients. Our results show 
weak agreement between the patient and clinician ratings and that 
both ratings separately can make a positive contribution to the 
predictive accuracy of overall survival prognostication. More spe-
cifically, our study demonstrates that including only patient scores 
(model 2) or including patient scores combined with clinician 
scores (model 4) provides a statistically significant relative gain in 
predictive accuracy for the symptoms fatigue, vomiting, nausea, 
and constipation compared with including clinician scores alone 
(model 3).
Although the inclusion of data regarding diarrhea contributed 
positively to survival estimation, low variability between patients at 
baseline might explain why including data on diarrhea confers low 
predictive value. There was relatively low baseline interpatient 
variability of diarrhea data in both patient-reported scores (SD = 
0.58; 95% CI = 1.23 to 1.31) and clinician-reported scores (SD = 
0.36; 95% CI = 1.08 to 1.12) compared with the other symptoms 
that we studied. Low interpatient variability at baseline was also 
reported for nausea and vomiting. Diarrhea, nausea, and vomiting 
are more strongly related to cancer treatment (eg, chemotherapy 
and/or radiotherapy) than to the presence of cancer itself, and 
therefore, baseline P values are lower for these symptoms com-
pared with the other symptoms that we studied. It is possible that 
diarrhea, nausea, and vomiting are better predictors for survival 
when ratings are taken throughout the course of treatment.
We found low agreement between clinician and patient scores 
for diarrhea and nausea. An explanation might be that for the 
clinician using the NCI-CTCAE scoring system, these symptoms 
can be measured by an exact number of the amount of stools or 
incidences of emesis that a patient experienced. However, for 
patients, diarrhea and nausea may have broader effects on their 
well-being, which are reflected in their scores (30). Low correla-
tion between the clinician and patient ratings might be explained 
by the use of two different approaches to measurement; this may 
imply that scoring behavior is imposed by the specific questions 
asked by the measurements. This idea has been discussed by Gotay 
(31), and it is exemplified in our study by the discrepancy in the 
EORTC QLQ-C30 pain and fatigue scores. Upon examining our 
EORTC QLQ-C30 pain scores, we can see that the clinician score 
for cancer pain is more highly correlated with the question “Have 
you had pain?” referring to the pain intensity, than with the ques-
tion “Did pain interfere with your daily activities?” which refers to 
the functional disability due to the pain. Upon examining our 
EORTC QLQ-C30 fatigue scores, we also notice that the 
agreement levels with clinician-reported scores are somewhat 
different depending on the specific questions asked of patients.
Table 2. The mean scores and 95% confidence intervals (CIs) for 
the symptoms pain, fatigue, vomiting, nausea, diarrhea, and 
constipation*
Clinical  
symptom
Patient score  
(EORTC QLQ-C30)†,  
mean (95% CI)
Clinician score  
(NCI-CTCAE)‡,  
mean (95% CI)
Pain 2.31 (2.26 to 2.36) 2.13 (2.07 to 2.18)
Fatigue 2.10 (2.05 to 2.15) 1.36 (1.33 to 1.40)
Vomiting 1.11 (1.08 to 1.14) 1.18 (1.15 to 1.21)
Nausea 1.38 (1.35 to 1.41) 1.20 (1.16 to 1.24)
Diarrhea 1.27 (1.23 to 1.31) 1.10 (1.08 to 1.12)
Constipation 1.50 (1.44 to 1.56) 1.11 (1.09 to 1.14)
* For purposes of comparison, we considered each of the following pairs to 
be identical responses: EORTC QLQ-C30 score 1 vs NCI-CTCAE score 0; 
EORTC QLQ-C30 score 2 vs NCI-CTCAE score 1; EORTC QLQ-C30 score 3 
vs NCI-CTCAE score 2; EORTC QLQ-C30 score 4 vs NCI-CTCAE scores 3 
and 4 combined. EORTC QLQ-C30 = European Organization for Research 
and Treatment of Cancer’s Quality of Life core questionnaire; NCI-CTCAE = 
National Cancer Institute’s Common Terminology Criteria for Adverse Events.
† In the EORTC QLQ-C30 questionnaire, the patient rated his or her symptoms 
on a 4-point ordinal scale in which a score of 1 meant “not at all,” a score of 
2 meant “a little,” a score of 3 meant “quite a bit,” and a score of 4 meant 
“very much.”
‡ In the NCI-CTCAE scoring, the clinician rated the patient’s symptoms on a  
5-point scale: a score of 0 meant “none or normal,” a score of 1 meant 
“mild,” a score of 2 meant “moderate,” a score 3 meant “severe,” and a 
score of 4 meant “life threatening or disabling.”
Table 3. Spearman (r) and kappa (k) correlation coefficients for comparisons between clinician and patient assessments of pain, 
fatigue, vomiting, nausea, diarrhea, and constipation*
Clinician (NCI-CTCAE) Patient (EORTC QLQ-C30) r† k (95% confidence interval)‡
Pain Have you had pain? 0.58 0.29 (0.26 to 0.33)
Did pain interfere with your daily activities? 0.50 0.27 (0.23 to 0.30)
Fatigue Did you need to rest? 0.30 0.07 (0.03 to 0.10)
Have you felt weak? 0.28 0.07 (0.03 to 0.10)
Were you tired? 0.30 0.08 (0.04 to 0.11)
Vomiting Have you vomited? 0.32 0.22 (0.13 to 0.30)
Nausea Have you felt nauseated? 0.32 0.14 (0.10 to 0.18)
Diarrhea Have you had diarrhea? 0.20 0.14 (0.07 to 0.20)
Constipation Have you been constipated? 0.38 0.16 (0.11 to 0.21)
* EORTC QLQ-C30 = European Organization for Research and Treatment of Cancer’s Quality of Life core questionnaire; NCI-CTCAE = National Cancer Institute’s 
Common Terminology Criteria for Adverse Events.
† As suggested by Cohen (22), a r value that is less than .30 indicates a weak relationship, a value between .30 and .50 indicates a moderate relationship, and a 
value greater than .50 indicates a strong relationship.
‡ As suggested by Landis and Koch (24), a k value less than 0.00 mean poor agreement; k between .00 and .20 slight agreement; k between .21 and .40 fair 
agreement; k between .41 and .60 moderate agreement; k between .61 and .80 substantial agreement; and k between .81 and 1.00 almost perfect agreement.
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We found a statistically significant difference between patient 
vs clinician reporting of fatigue and pain. As Basch et al. (32) suggest, 
clinicians may refrain from using the high end of the pain rating 
continuum until a patient’s disease progresses, in contrast with the 
patient, who has only his or her own current experience to use in 
making assessments of pain severity. On the other hand, patients 
may also minimize their symptoms, fearing that their active treat-
ment might be stopped if their clinical condition appears worse (10).
Our study does have potential limitations. One might speculate 
that the statistically significant differences between the C-indices 
are driven by the large sample size because the symptom scores 
make a relatively small contribution to predict overall survival 
compared with clinical and sociodemographic variables. Therefore, 
statistical significant differences in the prediction accuracy of dif-
ferent Cox models might not always translate into meaningful 
changes between the predictive value of the models, and further 
validation studies may be needed. Second, the large sample of dif-
ferent cancer sites did not allow us to include cancer-specific prog-
nostic variables that might be identified as key independent 
prognostic factors for survival (33–36). Another limitation to our 
study is that there is no evidence-based consensus regarding how 
to compare the scoring derived from the patient- vs clinician-
reported measurements. Based on the NCI-CTCAE manual (37), 
the NCI-CTCAE criteria should be used to assess any unfavorable 
symptom, sign, or disease that is temporarily associated with the 
use of a medical treatment, and it should not be used to grade 
the cancer itself. As such, baseline data are normally used to estab-
lish toxicity at the earliest time point to measure changes due to 
treatment. So, the normal purpose of the NCI-CTCAE baseline 
assessment differs from the EORTC QLQ-C30, in which the 
patient is asked to assess his quality of life more in general, inde-
pendent of treatment. These different purposes of assessment 
might provide some rationale as to why different scores and subse-
quently low levels of agreement are reported between patients and 
clinicians at baseline. Last, the fact that our data was collected 
from randomized controlled trials might have an impact on the 
generalization of our findings. Randomized controlled trials usually 
exclude elderly patients, patients with comorbidities, and patients 
who have severe symptom burdens at the time of study entry, and 
therefore our study was limited to a relative asymptomatic popula-
tion. Therefore, we invite the replication of our findings in a 
broader population of cancer patients or in observational studies.
Because the use of NCI-CTCAE scoring by clinicians has been 
accepted as a tool to rate the symptom burden of cancer, this study 
highlights the importance of patient-reported outcomes as subjec-
tive measures of the severity of symptoms that a cancer patient may 
experience. The use of NCI-CTCAE criteria to assess the prog-
nostic value of symptoms should be questioned, given the limita-
tion of the NCI-CTCAE as a sound psychometric instrument to 
value the symptom of a cancer burden as well as its inconsistency 
in application and evaluation. In addition, patient-reported out-
come tools like the EORTC QLQ-C30, which also assess psycho-
social and functional aspects of the cancer patient’s experience, 
allow for a broader assessment of the cancer burden than simple 
reports of symptoms. Patient-reported outcomes provide relevant 
information for cancer patients undergoing treatment, especially 
with regard to supportive and palliative care, symptom manage-
ment, and new treatments that extend survival (38). They are also 
useful in assisting health-care professionals to distinguish between 
treatments, and if needed, to modify therapeutic regimens.
Patient-reported outcomes, as an approved psychometric test and 
valid tool, might also play a vital role in clinical research. Stratifying 
at baseline for patients at higher risk for developing symptoms 
might improve the reliability of trial findings. Patient-reported 
symptoms may also have prognostic value; this use for patient 
reports should be assessed in upcoming clinical studies. Our study 
has shown that patient-reported outcomes add value to prediction 
models when combined with clinicians’ assessments. Also, patient-
reported outcomes should be used to rate symptom adverse events 
when monitoring patients in study trials, because it will improve 
clinical decision making in defining the best treatment options for 
patients. Similar suggestions have been made by Gotay et al. (16). 
Table 4. C-index from four Cox models to compare the predictive accuracy for overall survival using patient- and/or clinician-reported 
symptoms and P values for comparisons between models for pain, fatigue, vomiting, nausea, diarrhea, and constipation*
Clinical symptom
C-index
P¶ model 2 vs model 3 P¶ model 3 vs model 4Model 1† Model 2‡ Model 3§ Model 4ǁ
Pain .60 .62 .62 .63 .59 .44
Fatigue .60 .66 .63 .67 <.001 <.001
Vomiting .62 .64 .62 .64 .01 .01
Nausea .62 .65 .62 .65 <.001 <.001
Diarrhea .62 .62 .62 .62 .08 .52
Constipation .60 .62 .61 .62 .03 .01
* Four different Cox models were analyzed for each symptom, as described below. The C-index calculates the predictive accuracy from the Cox model to  
predict overall survival. (The C-index estimates the percentage in which the correct predictions derived from the Cox model and the observed survival order are  
in agreement, with C = 0.5 for a random model with no variables and C = 1 with a perfect order concordance.)
† Model 1 includes the sociodemographic and clinical variables alone.
‡ Model 2 includes the sociodemographic and clinical variables and patient symptom rating.
§ Model 3 includes the sociodemographic and clinical variables and clinician symptom rating.
ǁ Model 4 includes the sociodemographic and clinical variables and both patient and clinician symptom ratings.
¶ P values are from two-sided tests. Each P value tests the hypothesis that the predictions from one Cox model, indicated by the C-index is more concordant with 
the observed outcome than predictions from the other Cox model, indicated by the C-index, within paired predictions. In this analysis, we compared model 2 vs 
model 3 and model 3 vs model 4.
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Our study has indicated agreement at baseline; however, patient-
reported outcomes should also be assessed on a longitudinal basis. 
We therefore encourage future work in patient-reported outcome 
assessment on a longitudinal scale to monitor adverse events and 
to include patient-reported outcomes and patient-reported out-
come trajectories to support clinical decision making.
These elements have also been recognized by the NCI, which 
in 2008 launched the Patient-Reported Outcomes version of 
the Common Terminology Criteria for Adverse Events (PRO-
CTCAE) initiative to systematically collect and integrate patients’ 
ratings of their symptoms for adverse event reporting in cancer 
trials (39), reconfirming the general belief that patients themselves 
provide a unique and needed perspective in rating their own symp-
tom burden and quality of life. The PRO-CTCAE system provides 
a web-based platform to collect patient reports of symptoms they 
are experiencing while undergoing treatment. Currently, 81 symp-
toms are represented in the CTCAE (version 4.0) and have been 
identified to be amenable to patient reporting. This system, when 
complete, will enable the collection of complementary data from 
patients and clinicians (31) to provide information on symptom 
experience to guide cancer care.
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